CytomX Therapeutics (CTMX) Stock Forecast & Price Target

CytomX Therapeutics is attractive because its Varseta-M program is advancing with a clear near-term catalyst in 2H, where dose-optimization data, longer OS follow-up, and safety/efficacy results from the N=40 cohort could validate monotherapy dose selection and support a potential 3L or 4L mCRC registrational design planned for 1H27. The company also has multiple expansion shots on goal through Varseta-M combinations with bevacizumab and chemo, plus first-time plans to enter non-CRC EpCAM-expressing tumors such as GC/GEJ, PDAC, and BTC, broadening the addressable market beyond colorectal cancer. Financially, CTMX ended 2Q26 with $330M in cash and cash equivalents, plus $37M received in July from REGN, supporting a runway into at least 2H28 and reducing near-term funding risk.

CytomX Therapeutics is viewed negatively because its valuation remains highly dependent on an uncertain CX-2051 outcome in 3L colorectal cancer, where failure to generate favorable clinical data, trial delays, or regulatory setbacks could undermine the core thesis. Although 1Q26 cash, equivalents, and investments totaled $346.7M and runway extends to at least 2H28, the March 2026 offering added dilution risk and management still faces the need to fund multiple clinical readouts and a potential 1H27 pivotal start. Commercially, the company remains pre-revenue and exposed to lower-than-expected product sales, new competitors, and Varseta-M tolerability and line-of-therapy positioning, keeping the risk/reward profile unattractive.